Liquid biopsy enables genomic profiling in prostate cancer with high success rates. Learn more about its potential as a ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary ...

A quiet signal inside a tumor may soon guide how surgeons treat early lung cancer. Researchers now report that hidden genetic patterns can reveal whether a tumor has already begun to spread through ...

TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical study) ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go ...

Cardiometabolic health’s influence on outcomes in men with localized high-risk prostate cancer (HRPCa) treated with pre-operative ADT ± AR pathway inhibition (ARPI). This is an ASCO Meeting Abstract ...

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...